Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice

International Immunopharmacology

Volumn 4, Issue 7, 2004, Pages 851-862

  Zhu, Fu Gang ^a   Kandimalla, Ekambar R ^a   Yu, Dong ^a   Tang, Jimmy X ^a   Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

Author keywords

Asthma; CpG DNA; CpG motif; ELISA; enzyme linked immunosorbent assay; HE; hematoxylin and eosin; i.n.; IFN; Ig; IL; immunoglobulin; Immunoglobulins; immunomodulatory oligonucleotide; Immunotherapy; IMO; interferon; interleukin; OVA allergy; Th1 cytokines; Th2 cytokines

Indexed keywords

ALLERGEN; CPG DNA; CYTOKINE; DNA; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOMODULATING AGENT; OLIGONUCLEOTIDE; OVALBUMIN; SECOND GENERATION IMMUNOMODULATORY OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ALLERGY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CELL HYPERPLASIA; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; DISEASE MODEL; FEMALE; GOBLET CELL; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATORY INFILTRATE; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN MOTIF; SENSITIZATION; SPLEEN; SPLEEN CELL; TH1 CELL; TH2 CELL;

ANIMALS; CELLS, CULTURED; CYTOKINES; DEOXYGUANOSINE; DRUG COMBINATIONS; FEMALE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; LUNG; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; PNEUMONIA; SPLEEN; TH2 CELLS;

EID: 2942612298     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2004.03.009     Document Type: Article

References (47)

1. Robinson D.S. The Th1 and Th2 concept in atopic allergic disease. Chem. Immunol. 78:2000;50-61
2. Mattes J., Foster P.S. Regulation of eosinophil migration and Th2 cell function by IL-5 and eotaxin. Curr. Drug Targets Inflamm. Allergy. 2:2003;169-174
3. Izuhara K., Arima K., Yasunaga S. IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies. Curr. Drug Targets Inflamm. Allergy. 1:2002;263-269
4. Kelly H.W. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann. Allergy Asthma Immunol. 91:2003;326-334
5. Trujillo C., Erb K.J. Inhibition of allergic disorders by infection with bacteria or the exposure to bacterial products. Int. J. Med. Microbiol. 293:2003;123-131
6. Nahori M.A., Lagranderie M., Lefort J., Thouron F., Joseph D., et al. Effects of Mycobacterium bovis BCG on the development of allergic inflammation and bronchial hyperresponsiveness in hyper-IgE BP2 mice vaccinated as newborns. Vaccine. 19:2001;1484-1495
7. Hopfenspirger M.T., Parr S.K., Hopp R.J., Townley R.G., Agrawal D.K. Mycobacterial antigens attenuate late allergic response, airway hyperresponsiveness, and bronchoalveolar lavage eosinophilia in a mouse model of bronchial asthma. Int. Immunopharmacol. 1:2001;1743-1751
8. Hopfenspirger M.T., Agrawal D.K. Airway hyperresponsiveness, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice. J. Immunol. 168:2002;2516-2522
9. Aaby P., Shaheen S.O., Heyes C.B., Goudiaby A., Hall A.J., et al. Early BCG vaccination and reduction in atopy in Guinea-Bissau. Clin. Exp. Allergy. 30:2000;644-650
10. Kuramoto E., Yano O., Kimura Y., Baba M., et al. Oligonucleotide sequences required for natural killer cell activation. Jpn. J. Cancer Res. 83:1992;1128-1131
11. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549
12. Sato Y., Roman M., Tighe H., Lee D., Corr M., et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 273:1996;352-354
13. Halpern M.D., Kurlander R.J., Pisetsky D.S. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell. Immunol. 167:1996;72-78
14. Yamamoto S., Kuramoto E., Shimada S., Tokunaga T. In vitro augmentation of natural killer cell activity and production of interferon-α/β and -γ with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn. J. Cancer Res. 79:1988;866-873
15. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon-γ Proc. Natl. Acad. Sci. U. S. A. 93:1996;2879-2883
16. Zhao Q., Temsamani J., Zhou R.Z., Agrawal S. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 7:1997;495-502
17. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., et al. A Toll like receptor recognizes bacterial DNA. Nature. 408:2000;740-745
18. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.D., Sato Y., et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:1997;849-854
19. Broide D., Schwartze J., Tighe H., Gifford T., Nguyen M.D., et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J. Immunol. 161:1998;7054-7062
20. Kline J.N., Waldschmidt T.J., Businga T.R., Lemish J.E., Weinstock J.V., et al. Modulation of airway inflammation by CpG oligonucleotides in a murine model of asthma. J. Immunol. 160:1998;2555-2559
21. Sur S., Wild J.S., Choudhury B.K., Sur N., Alam R., et al. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J. Immunol. 162:1999;6284-6293
22. Marshall J.D., Abtahi S., Eiden J.J., Tuck S., Milley R., et al. Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J. Allergy Clin. Immunol. 108:2001;191-197
23. Broide D.H., Stachnick G., Castaneda D., Nayar J., Miller M., et al. Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J. Clin. Immunol. 21:2001;175-182
24. Kline J.N., Kitagaki K., Businga T.R., Jain V.V. Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am. J. Physiol., Lung Cell. Mol. Physiol. 283:2002;L170-L179
25. Horner A.A., Raz E. Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. J. Allergy Clin. Immunol. 110:2002;706-712
26. Hussain I., Kline J.N. CpG oligodeoxynucleotides: a novel therapeutic approach for atopic disorders. Curr. Drug Targets Inflamm. Allergy. 2:2003;199-205
27. Serebrisky D., Teper A.A., Huang C.K., Lee S.Y., Zhang T.F., et al. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J. Immunol. 165:2000;5906-5912
28. Santeliz J.V., VanNest V., Traquina P., Larsen E., Wills-Karp M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J. Allergy Clin. Immunol. 109:2002;455-462
29. Kitagaki K., Jain V.V., Businga T.R., Hussain I., Kline J.N. Immunomodulatory effects of CpG oligodeoxynucleotides on established Th2 responses. Clin. Diagn. Lab. Immunol. 9:2002;1260-1269
30. Agrawal S., Kandimalla E.R. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med. 8:2002;114-121
31. Agrawal S., Kandimalla E.R. Modulation of Toll-like receptor 9 responses through synthetic immunostimulatory motifs of DNA. Ann. N. Y. Acad. Sci. 1002:2003;30-42
32. Yu D., Zhao Q., Kandimalla E.R., Agrawal S. Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg. Med. Chem. Lett. 10:2000;2585-2588
33. Kandimalla E.R., Bhagat L., Yu D., Cong Y., Tang J., et al. Conjugation of ligands at the 5′-end of CpG DNA affects immunostimulatory activity. Bioconjug. Chem. 13:2002;966-974
34. Yu D., Kandimalla E.R., Bhagat L., Tang J.Y., Cong Y., et al. 'Immunomers' - novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res. 30:2002;4460-4469
35. Kandimalla E.R., Bhagat L., Wang D., Yu D., Tang J., et al. Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res. 31:2003;2393-2400
36. Bhagat L., Zhu F.G., Yu D., Tang J., Wang H., et al. CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem. Biophys. Res. Commun. 300:2003;853-861
37. Yu D., Zhu F.G., Bhagat L., Wang H., Kandimalla E.R., et al. Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem. Biophys. Res. Commun. 297:20002;83-90
38. Kandimalla E.R., Yu D., Zhao Q., Agrawal S. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. Bioorg. Med. Chem. 9:2001;807-813
39. Agrawal D.K., Edwan J., Kandimalla E.R., Yu D., Bhagat L., et al. Novel immunomodulatory oligonucleotides (IMOs) prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int. Immunopharmacol. 4:2004;127-138
40. Shirota H., Sano K., Kikuchi T., Tamura G., Shirato K. Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs. Am. J. Respir. Cell Mol. Biol. 22:2000;176-182
41. Chiang D.J., Ye Y.L., Chen W.L., Lee Y.L., Hsu N.Y., et al. Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation. Am. J. Respir. Crit. Care Med. 168:2003;575-580
42. Vasilakos J.P., Smith R.M., Gibson S.J., Lindh J.M., Pederson L.K., et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol. 204:2000;64-74
43. Park Y., Chang Y.S., Lee S.W., Cho S.Y., Kim Y.K., et al. The enhanced effect of a hexameric deoxyriboguanosine run conjugation to CpG oligodeoxynucleotides on protection against allergic asthma. J. Allergy Clin. Immunol. 108:2001;570-576
44. Chiaramonte M.G., Hesse M., Cheever A.W., Wynn T.A. CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism. J. Immunol. 164:2000;973-985
45. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG Oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1997;1623-1631
46. Zhang K. Accessibility control and machinery of immunoglobulin class switch recombination. J. Leukoc. Biol. 73:2003;323-332
47. van Ommen R., Vredendaal A.E., Savelkoul H.F. Suppression of polyclonal and antigen-specific murine IgG1 but not IgE responses by neutralizing interleukin-6 in vivo. Eur. J. Immunol. 24:1994;1396-1403